Mutual of America Capital Management LLC Decreases Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mutual of America Capital Management LLC cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 32.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,900 shares of the medical equipment provider’s stock after selling 11,607 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Zimmer Biomet were worth $2,525,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ZBH. Janney Montgomery Scott LLC lifted its position in shares of Zimmer Biomet by 181.0% during the third quarter. Janney Montgomery Scott LLC now owns 25,869 shares of the medical equipment provider’s stock worth $2,793,000 after purchasing an additional 16,663 shares in the last quarter. Asset Management One Co. Ltd. boosted its holdings in Zimmer Biomet by 4.2% in the third quarter. Asset Management One Co. Ltd. now owns 81,311 shares of the medical equipment provider’s stock valued at $8,778,000 after purchasing an additional 3,251 shares during the last quarter. M&G PLC grew its stake in Zimmer Biomet by 26.8% during the 3rd quarter. M&G PLC now owns 100,536 shares of the medical equipment provider’s stock valued at $10,858,000 after purchasing an additional 21,251 shares in the last quarter. Graypoint LLC raised its position in shares of Zimmer Biomet by 6.6% in the 3rd quarter. Graypoint LLC now owns 4,829 shares of the medical equipment provider’s stock valued at $521,000 after purchasing an additional 299 shares in the last quarter. Finally, Sittner & Nelson LLC boosted its stake in shares of Zimmer Biomet by 62.4% during the 3rd quarter. Sittner & Nelson LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $225,000 after buying an additional 801 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ZBH. Raymond James cut their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. JMP Securities reiterated a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Truist Financial restated a “hold” rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $124.15.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Trading Up 2.4 %

Shares of NYSE:ZBH opened at $107.87 on Friday. The firm has a market cap of $21.47 billion, a P/E ratio of 24.24, a P/E/G ratio of 1.95 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a 50 day moving average of $105.55 and a 200-day moving average of $107.22.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the company posted $2.20 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.